title: Counterpoint: should systemic lytic therapy be used for submassive pulmonary embolism? No.
authors: Department of Medicine, University of California San Francisco-Fresno Program, Fresno, CA.
authors: Kathryn L
authors: KL
authors: Bilello
authors: Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, School of Medicine, Sacramento, CA; Veterans Affairs Northern California Health Care System, Sacramento, CA. Electronic address: susan.murin@ucdmc.ucdavis.edu.
authors: Susan
authors: S
authors: Murin
mesh_terms: D000075202:Contraindications; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006470:Hemorrhage / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D017410:Practice Guidelines as Topic; D011655:Pulmonary Embolism / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000639:trends*; D018497:Ventricular Dysfunction, Right / Q000209:etiology / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents